Akebia Therapeutics, Inc. (AKBA)
NASDAQ: AKBA · Real-Time Price · USD
1.790
-0.030 (-1.65%)
At close: Nov 20, 2024, 4:00 PM
1.808
+0.018 (1.01%)
After-hours: Nov 20, 2024, 6:39 PM EST
Akebia Therapeutics Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Akebia Therapeutics stock have an average target of 5.75, with a low estimate of 4.00 and a high estimate of 7.50. The average target predicts an increase of 221.23% from the current stock price of 1.79.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for AKBA stock from 2 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 1 | 1 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 2 | 2 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $7.5 | Strong Buy | Reiterates | $7.5 | +318.99% | Oct 23, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $7.5 | Strong Buy | Reiterates | $7.5 | +318.99% | Oct 10, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $7.5 | Strong Buy | Reiterates | $7.5 | +318.99% | Oct 8, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $7.5 | Strong Buy | Reiterates | $7.5 | +318.99% | Sep 6, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $6 → $7.5 | Strong Buy | Maintains | $6 → $7.5 | +318.99% | Aug 12, 2024 |
Financial Forecast
Revenue This Year
172.11M
from 194.62M
Decreased by -11.57%
Revenue Next Year
182.66M
from 172.11M
Increased by 6.13%
EPS This Year
-0.25
from -0.28
EPS Next Year
-0.26
from -0.25
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 186.4M | 249.0M | 261.2M | ||
| Avg | 172.1M | 182.7M | 251.4M | ||
| Low | 149.1M | 126.7M | 239.2M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -4.2% | 44.7% | 43.0% | ||
| Avg | -11.6% | 6.1% | 37.6% | ||
| Low | -23.4% | -26.4% | 31.0% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -0.17 | 0.09 | 0.44 | ||
| Avg | -0.25 | -0.26 | 0.15 | ||
| Low | -0.32 | -0.46 | -0.13 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.